Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Cash from Operations: 2015-2024

Historic Cash from Operations for Apellis Pharmaceuticals (APLS) over the last 10 years, with Dec 2024 value amounting to -$87.9 million.

  • Apellis Pharmaceuticals' Cash from Operations rose 218.13% to $108.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.9 million, marking a year-over-year increase of 138.45%. This contributed to the annual value of -$87.9 million for FY2024, which is 85.23% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Cash from Operations of -$87.9 million as of FY2024, which was up 85.23% from -$594.7 million recorded in FY2023.
  • Apellis Pharmaceuticals' Cash from Operations' 5-year high stood at -$87.9 million during FY2024, with a 5-year trough of -$594.7 million in FY2023.
  • Moreover, its 3-year median value for Cash from Operations was -$513.7 million (2022), whereas its average is -$398.8 million.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Cash from Operations slumped by 250.88% in 2021, and later skyrocketed by 85.23% in 2024.
  • Yearly analysis of 5 years shows Apellis Pharmaceuticals' Cash from Operations stood at -$160.5 million in 2020, then plummeted by 250.88% to -$563.1 million in 2021, then grew by 8.77% to -$513.7 million in 2022, then dropped by 15.76% to -$594.7 million in 2023, then skyrocketed by 85.23% to -$87.9 million in 2024.